share_log

Shares of Companies With Alzheimer's Programs Are Trading After Biogen and Elsai Announced Lecanemab Treatment Its the Primary Endpoint and Reduced Clinical Decline on the Global Cognitive and Functional Scale.

Shares of Companies With Alzheimer's Programs Are Trading After Biogen and Elsai Announced Lecanemab Treatment Its the Primary Endpoint and Reduced Clinical Decline on the Global Cognitive and Functional Scale.

在Biogen和Elsai宣佈將Lecanemab治療作爲主要終點並減少全球認知和功能規模的臨床下降之後，擁有阿爾茨海默氏症計劃的公司的股票正在交易。
Benzinga ·  2022/09/28 19:41

Shares of companies with Alzheimer's programs are trading after Biogen and Elsai announced Lecanemab treatment its the primary endpoint and reduced clinical decline on the global cognitive and functional scale.

在Biogen和Elsai宣佈將Lecanemab治療作爲主要終點並減少全球認知和功能規模的臨床下降之後，擁有阿爾茨海默氏症計劃的公司的股票正在交易。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論